

SYSTEMATIC REVIEW OF HERPES ZOSTER EPIDEMIOLOGY: AVAILABLE EVIDENCE IN SPAIN RELATED TO SPECIFIC SUB-POPULATIONS

Mareque M¹, Oyagüez I¹, Morano R², Casado MA¹

¹ Pharmacoconomics & Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Spain; ² GlaxoSmithKline, Madrid, Spain

OBJECTIVES

- Herpes Zoster (HZ), the reactivation after a primary varicella zoster virus infection, is an important cause of morbidity around the world, especially among the adult population >50 years¹.
- Decline of cellular immunity related to age or immunosuppressive conditions are among the main reasons for HZ occurrence², but an increased risk of HZ seems to occur in other specific sub-populations with pre-existing medical conditions³.
- This study aims to review the available scientific evidence about incidence of HZ in the general population and in specific sub-populations, in Spain.

METHODS

- A systematic literature review (up to October 31, 2016) was carried out using Medline (PubMed) and Embase databases, combining several search terms: "herpes zoster", "diabetes mellitus" (DM), "chronic obstructive pulmonary disease" (COPD), "chronic heart failure", "mental disorders" and "immunocompromised".
- Three manual searches were additionally conducted: 1) non-indexed Spanish journals well-known in the infectious disease field; 2) supplements of local scientific congresses related with HZ; and 3) official epidemiological reports published by regional governments.
- Inclusion criteria were: English or Spanish publications reporting incidence rate or incidence proportion of HZ in the Spanish general population and/or specific sub-populations. No restrictions were applied on study design or population age.

RESULTS

- Among 264 references retrieved, 29 were finally included. Additionally, 5 regional epidemiological reports were identified and reviewed (Figure 1).
- HZ incidence rate in general population ranged from 2.1¹⁴ to 5.5⁷/1,000 inhabitants per year (Table 1). Higher HZ incidences were found for elderly population (>70 years)^{5,6,9} and women^{5,7,9,10}.

RESULTS

Table 1. Characteristics of HZ publications in general population

Type of study (years)	HZ incidence*	Type of study (years)	HZ incidence*
Retrospective ⁴ (2008-2009)	2.1/1,000 person-years (all ages)	Retrospective ¹¹ (2007-2009)	4.8/1,000 persons (15-100 years)
Retrospective ⁵ (2011)	4.9/1,000 person-years (>14 years)	Ambispective**** ¹² (2006-2007)	4.4/1,000 persons (15-49 years) 6.5/1,000 persons (50-59 years) 8.7/1,000 persons (60-69 years) 8.3/1,000 persons (70-100 years)
Retrospective ⁶ (2014)	4.9/1,000 person-years (Men >50 years) 12.0/1,000 person-years (70-74 years) 10.1/1,000 person-years (>75 years)	Regional registry ¹³ (2010-2015)	3.9/1,000 persons (all ages)
Retrospective ⁷ (2009-2014)	5.5/1,000 person-years (all ages)	Regional registry**** ¹⁴ (2012)	1.5/1,000 persons (all ages) 1.67/1,000 persons (50-59 years) 2.71/1,000 persons (60-69 years) 3.31/1,000 persons (70-79 years) 3.64/1,000 persons (>80 years)
Prospective ⁸ (2006-2007)	4.1/1,000 persons (general) 1.3/1,000 persons (<50 years) 6.7/1,000 persons (50-59 years) 9.7/1,000 persons (60-69 years) 11.1/1,000 persons (>70 years)	Regional registry**** ¹⁵ (2001-2013)	2.6/1,000 persons (all ages) 3.3/1,000 persons (45-64 years) 6.8/1,000 persons (65-84 years) 6.5/1,000 persons (>85 years)
Retrospective ⁹ (2007-2011)	4.8/1,000 persons (all ages) 6.2/1,000 persons (45-65 years) 11.9/1,000 persons (65-74 years) 10.9/1,000 persons (75-84 years)	Regional registry ¹⁶ (2015)	5.2/1,000 persons (all ages)
Retrospective ¹⁰ (2001-2010)	4.2/1,000 persons**	Regional registry ¹⁷ (2015)	3.7/1,000 persons (all ages)

*Incidence rate (n/person-years) or incidence proportion (n/persons); **Age range not specified; ***HZ incidence showed for population >50 years, additional info for other age ranges available in the report; ****This study partially includes results from reference 8. Here is presented additional data not included in reference 8; HZ: Herpes Zoster.

- Twenty references¹⁸⁻³⁷, assessed the incidence of HZ in specific sub-populations (Figure 2).
- An increased risk of HZ vs general population was reported for DM^{17,20} (24%), COPD²¹ (39%) and COPD patients receiving inhaled corticosteroids²¹ (61%).

Figure 1. Flow diagram for the systematic literature review and the selection of publications





Figure 2. Incidence proportion of HZ in specific sub-population



CONCLUSIONS

- Although studies conducted in Spain are heterogeneous, their results point towards a higher HZ incidence in specific sub-populations, i.e. age-specific and at risk, than in the general population.
- The present study could contribute to identify target age populations and at-risk groups if implementation of HZ vaccination programs in Spain would be considered.

References

1. Gnann JW, et al. N Engl J Med. 2002;347:340-6; 2. Johnson RW. Expert Rev Vaccines. 2010;9:21-6; 3. Forbes HJ, et al. BMJ. 2014;348:g2911; 4. Sancho Martínez R, et al. Gac Sanit. 2010;24:171; 5. Vega T, et al. Gac Sanit. 2012;26:93; 6. Cebollada AD, et al. Gac Sanit. 2016;30:1-X; 7. Ruiz Sopeña C, et al. Gac Sanit. 2015;29:1-VIII; 8. Cebrían-Cuenca AM, et al. BMC Fam Pract. 2010;11:33; 9. Cabrera Miranda LP, et al. Gac Sanit. 2012;26:133; 10. Gutiérrez L, et al. Gac Sanit. 2011;25:337; 11. Gutiérrez-Gimeno MV, et al. Gac Sanit. 2010;24:169; 12. Gutiérrez-Gimeno MV, et al. Gac Sanit. 2010;24:169; 13. Regional epidemiological report of Navarre. 2016; 14. Regional epidemiological report of Galicia. 2012; 15. Regional epidemiological report of Madrid. 2014; 16. Regional epidemiological report of Aragon. 2016; 17. Regional epidemiological report of Balearic Islands. 2016; 18. Muñoz P, et al. Medicine (Baltimore). 2010;89:166-75; 19. Rodríguez-Moreno A, et al. Transplant Proc. 2006;38:2416-8; 20. Muñoz-Quiles C, et al. Eur Geriatr Med. 2016;7:S176; 21. Muñoz Quiles C, et al. Value Health. 2016;19:A603-4; 22. Esteban-Vasallo MD, et al. Hum Vaccin Immunother. 2014;10:1650-60; 23. Aldaz P, et al. An Sist Sanit Navar. 2013;36:57-62; 24. García-Doval I, et al. Ann Rheum Dis. 2010;69:1751-55; 25. García-Vidal C, et al. Eur J Clin Microbiol Infect Dis. 2009;28:331-37; 26. Herrero JI, et al. Liver Transpl. 2004;10:1140-43; 27. Sempere A, et al. Bone Marrow Transplant. 1992;10:495-98; 28. Miguel MVH, et al. Arthritis Rheum. 2011;63:10 Suppl 1; 29. Muñoz-Pérez MA, et al. Br J Dermatol. 1998;139:33-9; 30. Jiménez-Pérez M, et al. Transplant Proc. 2006;38:2480-1; 31. Adell C, et al. Vacunas. 2004;5:53-7; 32. Fernández C, et al. Gac Sanit. 2015;29:1-VIII; 33. Álvarez-Argüelles ME, et al. Enferm Infecc Microbiol Clin. 2015;33:403; 34. Gilarranz R, et al. Enferm Infecc Microbiol Clin. 2014;32:333; 35. Catalán Eraso B, et al. Enferm Infecc Microbiol Clin. 2012;30:240; 36. López Soria L, et al. Enferm Infecc Microbiol Clin. 2013;30:233; 37. López Méndez P, et al. Neurología. 2010;25:211

Disclosures

GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium) funded this study (GSK study identifier: HO-17-17957) and all costs related to the development of the publications. Authors would like to thank Business & Decision Life Sciences platform for editorial assistance and publications coordination, on behalf of GSK. Stephanie Garcia coordinated abstract and poster development and editorial support. RM is an employee of the GSK group of companies and holds shares in this entity. MM, IO and MAC are employees of PORIB that received consultancy fees for the conduct of this study.

